Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiomeOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Two children under three years old with recurrent Clostridium difficile infection who had failed standard therapies. Both received fecal microbiota transplantation (FMT) as a rescue treatment.
How was it studied?
This is a case report from researchers at West Virginia University, Johns Hopkins, and the University of Maryland School of Medicine. The authors tracked clinical resolution of infection, growth outcomes, and fecal microbiota composition after FMT.
What did they find?
FMT resolved the clinical features of C difficile infection in both children. It also led to marked improvement in growth and increased gut microbiota diversity, with a notable rise in the proportion of Bacteroides.
Why it matters
Data on FMT efficacy in young children were previously lacking. These two cases suggest FMT can be effective for pediatric recurrent C difficile infection and may also support growth and microbiome recovery.